Related Experiment Video

Updated: Aug 13, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

GSTT1 and M1 polymorphisms in Hürthle thyroid cancer patients

Karmen Stankov1, Stefano Landi, Lydie Gioia-Patricola

  • 1Dipartimento di Medicina Interna, Cardioangiologia ed Epatologia, Unita' Operativa di Genetica Medica, Policlinico S. Orsola-Malpighi, Pad. 11, via Massarenti 9, 40138 Bologna, Italy.

Cancer Letters
|January 24, 2006
PubMed

Insights

Genetic variants in glutathione S-transferases (GST), specifically GSTT1 and GSTM1 null genotypes, were investigated for their association with thyroid carcinoma with cell oxyphilia (TCO). This study found no increased risk of TCO development linked to these GST null genotypes.

Area of Science:

  • Biochemistry
  • Genetics
  • Oncology

Background:

  • Glutathione S-transferases (GST) are crucial for cellular defense against genotoxic agents and reactive oxygen species (ROS).
  • GST gene polymorphisms, particularly null genotypes, have been implicated in various cancer types.
  • Oxyphilic thyroid tumors (TCO) are characterized by mitochondrial dysfunction, elevated ROS, and resistance to therapy, suggesting a potential role for GST variants.

Purpose of the Study:

  • To investigate the association between glutathione S-transferase T1 (GSTT1) and M1 (GSTM1) null allele variants and the risk of developing thyroid carcinoma with cell oxyphilia (TCO).
  • To explore whether specific GST null genotypes act as genetic susceptibility factors in the etiology of TCO.

Main Methods:

  • A case-control study design was employed.
  • Genotyping was performed to determine the frequencies of GSTT1 and GSTM1 null genotypes in TCO patients (cases) and healthy individuals (controls).
  • Statistical analysis, including odds ratios (OR) and 95% confidence intervals (CI), was used to assess the risk association.

Main Results:

  • The frequency of the GSTT1 null genotype was 19.2% in cases and 15.7% in controls (OR = 1.4; 95% CI, 0.70-2.81).
  • The frequency of the GSTM1 null genotype was 59% in cases and 55.6% in controls (OR = 1.24; 95% CI, 0.62-2.48).
  • Neither GSTT1 nor GSTM1 null genotypes showed a statistically significant association with an increased risk of TCO.

Conclusions:

  • The study concludes that GSTT1 and GSTM1 null genotypes do not appear to be significant risk factors for the development of thyroid carcinoma with cell oxyphilia.
  • These findings suggest that genetic variations in GSTT1 and GSTM1 may not play a substantial role in the susceptibility to TCO.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...